Drug development for hard - to - treat tumors and viruses
Search documents
Moleculin to Participate in the Virtual Investor Closing Bell Series
Globenewswire· 2025-11-26 14:15
Live video webcast with Walter Klemp, Chairman and Chief Executive Officer, on Tuesday, December 2nd at 4:00 PM ET HOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin will participate in the Virtual Investor Closing Bell Series on Tuesday, De ...